Table 2.
Mean MFM scale and QMT scores of participants before resveratrol administration.
| Type of muscular dystrophy | Total (N = 11) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Duchenne (N = 5) | Becker (N = 4) | Fukuyama (N = 2) | ||||||||||
| Number (%) | Range | Mean (SD) | Number (%) | Range | Mean (SD) | Number (%) | Range | Mean (SD) | Number (%) | Range | Mean (SD) | |
| MFM scale | 5 (100) | 2–63 | 22.2 (21.5) | 4 (100) | 38–85 | 64.5 (16.9) | 2 (100) | 2–10 | 6 | 11 (100) | 2–85 | 34.6 (29.3) |
| QMT pinch (N) | 5 (100) | 0.5–2.4 | 11.1 (0.7) | 4 (100) | 0.3–4.9 | 3.8 (2.1) | 2 (100) | 0.1–0.5 | 0.3 | 11 (100) | 0.1–4.9 | 1.9 (2.0) |
| QMT grip (kgf) | 3 (60) | 0.8–4.8 | 2.3 (1.8) | 4 (100) | 1.3–25.5 | 12.7 (9.5) | 0 (0) | – | – | 7 (64) | 0.8–25.5 | 8.3 (8.9) |
| QMT scapula elevation (kgf) | 4 (80) | 0.9–8.6 | 3.3 (3.1) | 4 (100) | 5.3–6.8 | 6.0 (0.6) | 2 (100) | 1.4–1.4 | 1.4 | 10 (91) | 0.9–8.6 | 4.0 (2.7) |
| QMT shoulder abducttion (kgf) | 1 (20) | – | 3.0 (–) | 4 (100) | 3.5–6.2 | 4.7 (1.0) | 0 (0) | – | – | 5 (45) | 3.0–6.2 | 4.4 (1.1) |
| QMT elbow flexion (kgf) | 1 (20) | – | 1.6 (–) | 4 (100) | 0.6–6.2 | 5.1 (3.0) | 1 (50) | – | 1.1 | 6 (55) | 0.6–6.2 | 3.9 (3.1) |
| QMT elbow extension (kgf) | 1 (20) | – | 2.8 (–) | 4 (100) | 3.1–9.2 | 5.7 (2.5) | 0 (0) | – | – | 5 (45) | 2.8–9.2 | 5.1 (2.5) |
| QMT hip flexion (kgf) | 1 (20) | – | 5.2 (–) | 4 (100) | 4.3–10.1 | 7.7 (2.2) | 0 (0) | – | – | 5 (45) | 4.3–10.1 | 7.2 (2.2) |
| QMT knee extension (kgf) | 2 (40) | 2.0–2.5 | 5.2 (–) | 4 (100) | 1.3–11.4 | 6.0 (3.9) | 0 (0) | – | – | 6 (55) | 1.3–11.4 | 4.8 (3.6) |
| QMT ankle dorsiflexion (kgf) | 1 (20) | – | 5.2 (–) | 4 (100) | 3.2–7.9 | 5.4 (2.2) | 1 (50) | – | 1.4 | 6 (55) | 1.4–7.9 | 4.4 (2.4) |
| Creatine kinase (unit/l) | 5 (100) | 200–9518 | 2522 (3518) | 4 (100) | 431–2807 | 1601 (1020) | 2 (100) | 840–1981 | 1411 | 11 (100) | 200–9518 | 1985 (2512) |